Sorafenib for treatment of hepatocellular carcinoma: A systematic review

Digestive Diseases and Sciences

Volumn 57, Issue 5, 2012, Pages 1122-1129

  Xie, Bingru ^a   Wang, David H ^a   Spechler, Stuart Jon ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Cirrhosis; Hepatocellular carcinoma; Sorafenib; Systematic review; Transarterial chemoembolization

Indexed keywords

DOXORUBICIN; FLUOROURACIL; SORAFENIB; BENZENESULFONIC ACID DERIVATIVE; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRIDINE DERIVATIVE; RAF PROTEIN;

ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER STAGING; CANCER SURVIVAL; CHEMOEMBOLIZATION; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FATIGUE; HAND FOOT SYNDROME; HEPATITIS B; HUMAN; LIVER CELL CARCINOMA; MONOTHERAPY; OVERALL SURVIVAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; TREATMENT RESPONSE; TUMOR GROWTH; CELL PROLIFERATION; CLINICAL PROTOCOL; DRUG EFFECT; LIVER; LIVER CIRRHOSIS; LIVER TUMOR; METABOLISM; METHODOLOGY; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; TREATMENT OUTCOME; VIRUS HEPATITIS;

ANTINEOPLASTIC PROTOCOLS; BENZENESULFONATES; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; CHEMOEMBOLIZATION, THERAPEUTIC; HAND-FOOT SYNDROME; HEPATITIS, VIRAL, HUMAN; HUMANS; LIVER; LIVER CIRRHOSIS; LIVER NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN KINASE INHIBITORS; PYRIDINES; RAF KINASES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTOR PROTEIN-TYROSINE KINASES; TREATMENT OUTCOME;

EID: 84863606957     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-012-2136-1     Document Type: Review

References (51)

1. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74-108.
2. Pons-Renedo F, Llovet JM. Hepatocellular carcinoma: a clinical update. Med Gen Med. 2003;5:11.
3. American Cancer Society. Cancer Facts and Figures 2010. Atlanta: American Cancer Society; 2010.
4. El-Serag HB. Epidemiology of hepatocellular carcinoma in USA. Hepatol Res. 2007;37:S88-S94.
5. El-Serag HB, Davila JA, Petersen NJ, et al. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med. 2003;139:817-823.
6. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med. 1999;340: 745-750.
7. NHANES III Data. http://www.cdc.gov/NCIDOD/Diseases/hepatitis/c/plan/HCV- infection.html; 2008.
8. Calvisi DF, Ladu S, Gorden A, et al. Ubiquitous activation of Ras and Jak/stat pathways in human HCC. Gastroenterology. 2006; 130:1117-1128.
9. Marotta F, Vangieri B, Cecere A, et al. The pathogenesis of hepatocellular carcinoma is multifactorial event. Novel immunological treatment in prospect. Clin Ter. 2004;155:187-199.
10. Avila MA, Berasain C, Sangro B, et al. New therapies for hepatocellular carcinoma. Oncogene. 2006;25:3866-3884.
11. Goodsell DS. The molecular perspective: the Ras oncogene. Oncologist. 1999;4:263-264.
12. Stockl L, Berting A, Malkowski B, et al. Integrity of c-Raf-1/MEK signal transduction cascade is essential for hepatitis B virus gene expression. Oncogene. 2003;22:2604-2610.
13. Giambartolomei S, Covone F, Levrero M, et al. Sustained activation of the Raf/MEK/Erk pathway in response to EGF in stable cell lines expressing the hepatitis C virus (HCV) core protein. Oncogene. 2001;20:2606-2610.
14. Shimotohno K, Watashi K, Tsuchihara K, et al. Hepatitis C virus and its roles in cell proliferation. J Gastroenterol. 2002;37:50-54.
15. Gollob JA, Wilhelm S, Carter C, et al. Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway. Semin Oncol. 2006;33:392-406.
16. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004;64:7099-7109.
17. Wilhelm SM, Adnane L, Newell P, et al. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther. 2008;7:3129-3140.
18. Rahmani M, Davis EM, Bauer C, et al. Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation. J Biol Chem. 2005;280:35217-35227.
19. Yu C, Bruzek LM, Meng XW, et al. The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006. Oncogene. 2005;24:6861-6869.
20. Molhoek KR, Griesemann H, Shu J, et al. Human melanoma cytolysis by combined inhibition of mammalian target of rapamycin and vascular endothelial growth factor/vascular endothelial growth factor receptor-2. Cancer Res. 2008;68:4392-4397.
21. Takimoto CH, Awada A. Safety and anti-tumor activity of sorafenib (Nexavar) in combination with other anti-cancer agents: a review of clinical trials. Cancer Chemother Pharmacol. 2008;61:535-548.
22. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097.
23. http://www.ncbi.nlm.nih.gov/pubmed.
24. http://www.isiknowledge.com.
25. https://register.clinicaltrials.gov/.
26. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378-390.
27. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10:25-34.
28. Abou-Alfa GK, Schwartz L, Ricci S, et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2006;24:4293-4300.
29. Massa E, Stadier C, et al. Efficacy, safety and impact on quality of life of a treatment with sorafenib in elderly cancer patients with advanced hepatocellular carcinoma. Result of a phase II study. Ann Oncol. 2009;20:s65.
30. Yau T, Chan P, Ng KK, et al. Phase 2 open-label study of singleagent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population: presence of lung metastasis predicts poor response. Cancer. 2009;115:428-436.
31. Furuse J, Ishii H, Nakachi K, et al. Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma. Cancer Sci. 2008;99:159-165.
32. Castroagudin JF, Molina E, et al. Short-term efficacy and safety of treatment of advanced hepatocellular carcinoma with sorafenib. J Hepatol. 2008;48:s141-s142.
33. Prete SD, Montella L, Caraglia M, et al. Sorafenib plus octreotide is an effective and safe treatment in advanced hepatocellular carcinoma: multicenter phase II So LAR.study. Cancer Chemother Pharmacol. 2010;66:837-844.
34. Petrini I, Muul LM, et al. A phase II trial of sorafenib in combination with 5-fluorouracil continuous infusion in patients with advanced hepatocellular carcinoma: preliminary data. J Clin Oncol. 2009;27:4592.
35. Gianluca D, Muul LM, et al. Prospective phase II study of combination sorafenib plus mitomycin-c in the treatment of advanced hepatocellular carcinoma. Ann Oncol. 2009;20:8.
36. Yau T, Chan P, et al. Phase II trial of sorafenib with capecitabine and oxaliplatin (SECOX) in patients with locally advanced or metastatic hepatocellular carcinoma. EJC Suppl. 2009;7:20-21.
37. Abou-Alfa GK, Johnson P, Knox JJ, et al. Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial. JAMA. 2010;304:2154- 2160.
38. Hsu CH, Shen YC, Lin ZZ, et al. Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma. J Hepatol. 2010;53:126-131.
39. Giuliana F, Rosenberg A, et al. Sorafenib plus cisplatin and gemcitabine in the treatment of advanced hepatocellular carcinoma: a phase II study by the Grupo Oncologico Dell'Italia Meridonale (PROT. GOIM 2705). Cancer Treat Rev. 2010;36:S96.
40. Erhardt A, Kollings F, et al. First-in-men demonstration of sorafenib plus TACE for the treatment of advanced hepatocellular carcinoma (SOCRATES trial). Hepatology. 2009;50:1080A.
41. Reyes DK, Azad N, et al. Phase II trial of sorafenib wit doxirubicin eluting bead-transarterial chemoembolization (DEB-TACE) for patients with hepatocellular carcinoma: interim safety and efficacy analysis. Hepatology. 2009;50:6A-7A.
42. Richly H, Schultheis B, Adamietz IA, et al. Combination of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma: results from a phase I extension trial. Eur J Cancer. 2009;45:579-587.
43. Faivre S, Feng L, et al. Phase I safety, pharmacokinetic, and pharmacodynamic study of AVE 1642, a human monoclonal antibody inhibiting the insulin-like grouth factor-1 receptor (IGF- 1R/CD221), administered as single agent and in combination with sorafinib as first line therapy in patients with advanced hepatocellular carcinoma. Hepatology. 2010;52:S 466A-288.
44. Dufour JF, Hoppe H, Heim MH, et al. Continuous administration of sorafenib in combination with transarterial chemoembolization in patients with hepatocellular carcinoma: results of a phase I study. Oncologist. 2010;15:1198-1204.
45. Pinter M, Smith W, et al. An interim safety analysis of sorafenib plus transarterial chemoembolization in hepatocellular carcinoma- a phase I/II pilot study (SORATACE-1 trial). Hepatology. 2010;52:1157A-1759.
46. Pawlik TM, Reyes DK, Cosgrove D, et al. Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma. J Clin Oncol. 2011;29:3960-3967.
47. Yang CH, Lin WC, Chuang CK, et al. Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy. Br J Dermatol. 2008;158:592-596.
48. Chan AO, Yuen MF, Hui CK, et al. A prospective study regarding the complications of transcatheter intraarterial lipiodol chemoembolization in patients with hepatocellular carcinoma. Cancer. 2002;94:1747-1752.
49. Shweiki D, Itin A, Soffer D, et al. Vascular endothelial growth factor induced by hypoxic may mediate hypoxic-initiated angiogenesis. Nature. 1992;359:843-845.
50. Li X, Feng GS, Zheng CS, et al. Influence of transarterial chemoembolization on angiogenesis and expression of vascular endothelial growth factor and basic fibroblast growth factor in rat with Walker-256 transplanted hepatoma: an experimental study. World J Gastroenterol. 2003;9:2445-2449.
51. Lee JK, Chung YH, et al. Recurrences of hepatocellular carcinoma following initial remission by transcatheter arterial chemoembolization. J Gastroenterol Hepatol. 2002;17:52-58.